Treatment Approach for MSI-H/dMMR CRC

 

Treatment Approach for MSI-H/dMMR CRC
05:20

ecancer

ASCO 2021 Update on Pembrolizumab vs. Chemo in MSI-H/dMMR mCRC: Final OS Results From the KEYNOTE-177 Trial

FEATURING Thierry André
  • 217 views
  • August 4, 2021
30:44

LARVOL

ASCO 2021 Highlights on Advanced Gastrointestinal Cancers: 1L Nivo + Chemo in Advanced GC/GEJC/EAC, Pembro in MSI-H/dMMR mCRC, and T-DXd in HER2+ mCRC

FEATURING Mohamed Salem, Mark Lewis, Kevin Knopf
  • 188 views
  • October 28, 2021
  • 1
27:09

2021 Virtual ESMO Review

ESMO 2021 Upper GI Updates: Advanced ESCC and GEJ, HER2+ GC, CAR T, MSI-H/dMMR Cancers

FEATURING Samuel Klempner
  • 216 views
  • November 8, 2021
  • 1
20:33

UChicago Medicine: Sixth Annual Updates in Digestive Diseases

Colon Cancer Screening and Surveillance in 2021

FEATURING Neil Sengupta
  • 733 views
  • November 5, 2021
  • 4
16:08

UChicago Medicine: Sixth Annual Updates in Digestive Diseases

Updates in Genetic Testing for Familial Cancers

FEATURING Christine Drogan
  • 648 views
  • November 5, 2021
  • 3
07:51

University of Colorado Cancer Center

Updates in dMMR/MSI CRC: Overview of Recent Immunotherapy Advances

FEATURING Wells Messersmith
  • 281 views
  • July 7, 2021
  • 2
18:08

10th Annual Winship Cancer Institute Gastrointestinal Cancer Virtual Symposium

Updates in Management of mCRC in Era of Comprehensive Genomic Analysis

FEATURING Christina Wu
  • 53 views
  • July 6, 2021
44:02

Total Health

Expert Discussion on mCRC: Pembro vs. Chemo for MSI-H dMMR Disease, Trifluridine/Tipiracil + Bev for Untreated Patients, ctDNA in Postoperative Setting

FEATURING Shikha Jain, May Cho, Cathy Eng, Arturo Loaiza-Bonilla, Aparna Parikh
  • 283 views
  • March 10, 2021
  • 1
09:44

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liquid Biopsy in Advanced Gastrointestinal Cancers

FEATURING Pashtoon Kasi
  • 359 views
  • January 26, 2022
  • 2
14:06

ASCO GI 2022 Conference Coverage

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic GI Cancers

FEATURING Arvind Dasari
  • 238 views
  • February 3, 2022
  • 1
34:34

UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

Immunology & IO in Lynch Syndrome: Immune System, MSI & Hereditary Mismatch Deficiency, Current Therapies & Immuno-Prevention

FEATURING Michael J. Hall
  • 110 views
  • February 16, 2021
  • 2
20:38

Nilofer Saba Azad

Emerging Approaches for Immunotherapy in CRC

  • 321 views
  • January 5, 2021
  • 1
20:26

Collaborative Group of the Americas for Inherited Gastrointestinal Cancers

Incidental Findings From Somatic Testing and Implications for Hereditary GI Cancers

FEATURING Zsofia Stadler
  • 138 views
  • February 23, 2022
  • 1
10:48

Daniel Ahn

Chemo & IO in MSI-H mCRC: What the Oncologist Should Know

  • 641 views
  • March 2, 2022
  • 5
24:51

UNC Lineberger Comprehensive Cancer Center

Updates in Treatment Sequencing by Molecular Profile in CRC and Biliary Cancers

FEATURING Hanna K. Sanoff
  • 255 views
  • March 9, 2022
  • 1
13:15

Penn Medicine Abramson Cancer Center

Colorectal Liver Metastases: Liver-Directed Therapies - Embolization and Percutaneous Ablation

FEATURING Michael Soulen
  • 1,850 views
  • March 2, 2022
  • 12
15:26

Chiara Cremolini

Utilizing Single-Agent Immunotherapy in MSI-H CRC

  • 160 views
  • March 14, 2022
19:03

2022 West Oncology Conference

Therapeutic Advances in CRC: The Real Deal or Just Hype?

FEATURING Van Morris
  • 256 views
  • March 14, 2022
11:02

Cleveland Clinic Taussig Cancer Institute

Prognostic and Predictive Value of Microsatellite Instability Status Among Patients With Colorectal Cancer

FEATURING Firas Baidoun
  • 192 views
  • March 16, 2022
  • 1
04:11

ASCO 2022 Conference Coverage

ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

FEATURING Michael Overman
  • 1,075 views
  • June 9, 2022
43

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

FEATURING Michael Overman
  • 11 views
  • June 9, 2022
08:41

ASCO 2022 Conference Coverage

ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC: Long-Term Follow-Up of Cohorts B and D

FEATURING Richard Kim
  • 2,338 views
  • June 9, 2022
  • 8
01:02

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC in KEYNOTE-651: Long-Term Follow-Up of Cohorts B and D

FEATURING Richard Kim
  • 353 views
  • June 9, 2022
  • 3